

STUDY ON DAPTOMYCIN USE AS A FIRST STEP TOWARDS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME

García-Sánchez S^{1,2}, García-Moreno FJ^{1,2}, Rodríguez-González C^{1,2}, Chamorro-De Vega E^{1,2}, García-Martín E^{1,2}, Valerio-Minero M^{2,3}, Muñoz P^{2,3}, Bouza E^{2,3}, Herranz-Alonso A^{1,2}, Sanjurjo-Sáez M^{1,2}

¹Servicio de Farmacia. Hospital General Universitario Gregorio Marañón.

²Instituto de Investigación Sanitaria Gregorio Marañón (IISGM). Madrid, España

³Servicio de Microbiología y Enfermedades Infecciosas. Hospital General Universitario Gregorio Marañón.

OBJECTIVE

Background: The use of daptomycin has increased in Spain since its approval and there is a great variability in the dosage and in the criteria for its use in clinical practice.

OBJECTIVE: To report the real use of daptomycin in clinical practice including its efficacy and tolerability as a first measure for the establishment of improvement actions.


METHODS

- Study**
Observational, retrospective
- Eligible criteria**
Patients who started treatment with daptomycin
- Inclusion time**
01/01/2017 – 31/12/2017
- Follow up**
Until hospital discharge

Variables


Patient	Infection	Treatment
Age, sex	Type of infection	Previous, concomitant and subsequent antibiotics
Comorbidities	Microbiological results	Dosage of daptomycin
Analytical parameters	Clinical outcome	Adverse events

RESULTS



CONCLUSIONS

- Daptomycin is a well-tolerated and effective drug but is often prescribed empirically or in infections not caused by *S. aureus* methicillin resistant.
- The follow-up of patients treated with daptomycin should be considered a priority intervention within the Antimicrobial Stewardship Programmes.



<http://www.eahp.eu/24-4CPS-053>

